United States - English - NLM (National Library of Medicine)

e5 pharma, llc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide oral suspension is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: - adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. - infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. diazoxide should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide should be considered. the use of diazoxide for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh the possible risks.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide oral suspension is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered. the use of diazoxide oral suspension for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - diazoxide, quantity: 15 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - diazoxide is a non-diuretic antihypertensive agent. it is administered by rapid iv injection for emergency reduction of blood pressure in patients with malignant hypertension when prompt and urgent decrease in diastolic pressure is required. diazoxide injection bp is recommended in the treatment of hypertensive crises associated with acute glomerular nephritis, acute hypertensive encephalopathy, cerebral haemorrhage or congestive heart failure. diazoxide is usually effective in patients with refractory hypertension not responsive to other agents. it has also been used in the treatment of chronic hypertension to control elevated blood pressure before commencement of therapy with oral antihypertensive agents. in order to reduce the danger of haemorrhage due to elevated blood pressure, diazoxide injection bp may be used in hypertensive patients undergoing diagnostic procedures such as renal biopsy or arteriography

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - sodium oxidronate, quantity: 3.15 mg - injection, powder for - excipient ingredients: sodium chloride; stannous chloride dihydrate; dilute hydrochloric acid; gentisic acid; sodium hydroxide - technetium [99m tc] sodium oxidronate is a diagnostic skeletal imaging agent to demonstrate areas of altered osteogenesis in adult patients.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - diazoxide (unii: o5cb12l4fn) (diazoxide - unii:o5cb12l4fn) - diazoxide 50 mg in 1 ml - proglycem (oral diazoxide) is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. infants and children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. proglycem may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. proglycem should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. when other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with proglycem should be considered. the use of proglycem for functional hypoglycemia is contraindicated. the drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh the possible risks.

United States - English - NLM (National Library of Medicine)

curium us llc - oxidronate disodium (unii: h852yk87wp) (oxidronic acid - unii:71mr4v32ti) - oxidronate disodium 3.15 mg - technescan hdp tc 99m is a diagnostic skeletal imaging agent used to demonstrate areas of altered osteogenesis in adult and pediatric patients. none known. all procedures should be conducted using waterproof gloves. use shielded syringe during transport and administration of tc 99m solutions. - remove plastic disc from technescan hdp vial and cleanse top by swabbing with alcohol. note: if dose is for a single adult patient or for a pediatric patient, see unit dose preparation method below. - place vial in lead vial shield. add 3 to 6 ml of sodium pertechnetate tc 99m solution and secure with a fitted lead cover. in choosing the amount of tc 99m radioactivity to be used, the number of doses desired, the activity of each dose [recommended adult dose is 555 mbq (15 mci) with a range of 370 to 740 mbq (10 to 20 mci)] and radioactive decay must be taken into account. the recommended maximum amount of tc 99m radioactivity to be added to the vial is 11.1 gigabecquerels (300 mci). note: the contents of the vial are

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - copper (cu) present as cupric hydroxide - water dispersible granule - copper (cu) present as cupric hydroxide mineral-copper active 500.0 g/kg - fungicide

United States - English - NLM (National Library of Medicine)

prugen, inc. - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 70 mg in 1 ml - indications and usage: prtm benzoyl peroxide wash is indicated for the topical treatment of acne vulgaris. contraindications: prtm benzoyl peroxide wash is contraindicated in persons with a known hypersensitivity to any of its ingredients.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 5 g in 100 g - benzoyl peroxide gel 5% and 10% are indicated for use in the topical treatment of mild to moderate acne vulgaris. benzoyl peroxide gel 5% and 10% may be used as an adjunct in acne treatment regimens including antibiotics, retinoic acid products, and sulfur/salicylic acid containing preparations. benzoyl peroxide gel 5% and 10% should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the products.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - benzoyl peroxide, quantity: 50 mg/g; clindamycin phosphate, quantity: 11.9 mg/g (equivalent: clindamycin, qty 10 mg/g) - gel - excipient ingredients: silicon dioxide; purified water; glycerol; sodium hydroxide; disodium lauril sulfosuccinate; dimeticone 100; carbomer 980; poloxamer; disodium edetate - for the topical treatment of comedo, papules and pustular acne vulgaris.